MCID: VPM001
MIFTS: 50

Vipoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Vipoma

MalaCards integrated aliases for Vipoma:

Name: Vipoma 12 74 52 58 54 43 15 71
Pancreatic Vipoma 52 17 71
Diarrheogenic Islet Cell Tumor 52 58
Vip-Secreting Tumor 52 58
Pancreatic Cholera 58 71
Wdha Syndrome 58 54
Malignant Vasoactive Intestinal Peptide-Secreting Tumor 12
Watery Diarrhea-Hypokalemia-Achlorhydria Syndrome 58
Vasoactive Intestinal Peptide-Secreting Tumor 12
Vasoactive Intestinal Peptide-Producing Tumor 52
Vasoactive Intestinal Peptide Tumor 52
Verner-Morrison Syndrome 58
Vip- Secreting Tumor 12
Vipoma, Malignant 12
Malignant Vipoma 71

Characteristics:

Orphanet epidemiological data:

58
vipoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare gastroenterological diseases
Rare endocrine diseases


Summaries for Vipoma

NIH Rare Diseases : 52 A VIPoma is a rare cancer caused by a type of pancreatic neuroendocrine tumor , which is tumor that arises from cells that produce hormones - allowing the tumor itself to produce hormones. A VIPoma secretes vasoactive intestinal peptide (VIP), a hormone that stimulates the secretion (and inhibits the absorption) of sodium, chloride, potassium and water within the small intestine. Excessive secretion can increase bowel motility and lead to signs and symptoms such as abdominal pain and cramping, severe watery diarrhea, dehydration, flushing of the face, muscle cramps due to low potassium levels (hypokalemia ), and weight loss. When a person has a VIPoma and these associated symptoms, it is referred to as VIPoma syndrome , also called WDHA syndrome or Verner-Morrison syndrome. The majority of people with a VIPoma have VIPoma syndrome. VIPomas are usually diagnosed in middle-aged adults or in young children. Tests used to diagnose a VIPoma may include blood tests (including VIP level), imaging studies such as a CT scan or MRI , and examination of a stool sample. Unfortunately, even though these tumors are slow-growing, the majority of VIPomas are metastatic (have spread to other parts of the body) at the time of diagnosis. The underlying cause of VIPomas is not yet known. Management typically first involves treating dehydration with fluids and correcting the imbalance of hormones and other substances (metabolic abnormalities) in the body. Medications such as octreotide and lanreotide can usually stop the diarrhea and inhibit the secretion of VIP. Surgery typically follows in order to remove the tumor. When there is no evidence of metastasis , complete removal of the tumor is the only possible cure. The majority of metastatic cases will not be cured by surgery, but symptoms may be managed and prolonged survival is often possible due to the slow-growing nature of these tumors. Targeted therapy or chemotherapy may also be used for people with progressive, advanced disease. The median survival of people with VIPomas is 96 months, but long-term survival mainly depends on the tumor grade , staging , and whether all or most of the tumor can be removed.

MalaCards based summary : Vipoma, also known as pancreatic vipoma, is related to malignant pheochromocytoma and pancreatic cholera, and has symptoms including diarrhea An important gene associated with Vipoma is VIP (Vasoactive Intestinal Peptide), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Fentanyl and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and small intestine, and related phenotypes are hypokalemia and neoplasm of the pancreas

Wikipedia : 74 A VIPoma or vipoma (/vɪˈpoʊmə/) is a rare endocrine tumor that overproduces vasoactive intestinal... more...

Related Diseases for Vipoma

Diseases related to Vipoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 malignant pheochromocytoma 31.2 SST CHGA CALCA
2 pancreatic cholera 30.9 VIP SST SPINK5 SCT MEN1 GHRH
3 secretory diarrhea 30.6 VIP SST
4 ganglioneuroma 30.5 VIP SST CHGA
5 diarrhea 30.4 SST SCT NTS MEN1 GAST CALCA
6 small cell carcinoma 30.3 GAST CHGA CALCA
7 ileus 30.2 VIP SST NTS CALCA
8 glucagonoma 30.1 VIP SST SCT GAST CHGA
9 parathyroid adenoma 30.0 MEN1 GAST CHGA CALCA
10 pheochromocytoma 30.0 VIP SST MEN1 CHGA CALCA
11 paraganglioma 29.8 SST MEN1 CHGA CALCA
12 primary hyperparathyroidism 29.8 MEN1 GAST CHGA CALCA
13 neuroendocrine carcinoma 29.8 SST MEN1 GAST CHGA CALCA
14 hyperparathyroidism 29.7 SCT MEN1 GAST CHGA CALCA
15 hypoglycemia 29.3 SST GHRH GH1 GAST
16 islet cell tumor 29.3 VIP SST SPINK5 SCT MEN1 GHRH
17 hyperprolactinemia 29.2 VIP SST GHRH GH1
18 insulinoma 29.2 SST SCT MEN1 GAST CHGA
19 gastrinoma 29.1 VIP SST SCT MEN1 GAST CHGA
20 carcinoid syndrome 28.9 SST NTS MEN1 GHRH CHGA CALCA
21 pancreatic endocrine carcinoma 28.9 SSTR3 SST SPINK5 MEN1 GAST CHGA
22 neuroendocrine tumor 28.7 VIP SST SCT NTS MEN1 GHRH
23 multiple endocrine neoplasia, type i 28.6 VIP SST SPINK5 SCT MEN1 GHRH
24 zollinger-ellison syndrome 28.5 SST SCT NTS MEN1 GHRH GAST
25 somatostatinoma 28.1 VIP SST SPINK5 MEN1 GHRH GAST
26 adenoma 28.0 SST SMAD4 MEN1 GHRH GH1 CHGA
27 pancreatic cancer 27.8 VIP SST SMAD4 SCT NTS MEN1
28 small intestinal vasoactive intestinal peptide producing tumor 12.8
29 pancreatic vasoactive intestinal peptide producing tumor 11.7
30 hypokalemia 10.8
31 metabolic acidosis 10.5
32 multiple endocrine neoplasia 10.5
33 insulinomatosis and diabetes mellitus 10.4
34 glucose intolerance 10.4
35 large cell carcinoma 10.4
36 autoimmune atrophic gastritis 10.4 GAST CHGA
37 duodenal benign neoplasm 10.4 SST CHGA
38 ampulla of vater neoplasm 10.4 SST CHGA
39 mixed ductal-endocrine carcinoma 10.4 GAST CHGA
40 leprosy 2 10.4 VIP CALCA
41 goblet cell carcinoid 10.4 GAST CHGA
42 cervical neuroblastoma 10.4 VIP CHGA
43 gastric hemangioma 10.4 SST CHGA
44 gastric antral vascular ectasia 10.4 SST GAST
45 extracranial neuroblastoma 10.3 VIP CHGA
46 adrenal gland pheochromocytoma 10.3
47 cluster headache 10.3 VIP CALCA
48 ureter small cell carcinoma 10.3 CHGA CALCA
49 atypical follicular adenoma 10.3 NTS CALCA
50 laryngeal neuroendocrine tumor 10.3 CHGA CALCA

Graphical network of the top 20 diseases related to Vipoma:



Diseases related to Vipoma

Symptoms & Phenotypes for Vipoma

Human phenotypes related to Vipoma:

58 31 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypokalemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002900
2 neoplasm of the pancreas 58 31 hallmark (90%) Very frequent (99-80%) HP:0002894
3 secretory diarrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0005208
4 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
5 malabsorption 58 31 frequent (33%) Frequent (79-30%) HP:0002024
6 dehydration 58 31 frequent (33%) Frequent (79-30%) HP:0001944
7 generalized muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0003324
8 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
9 erythema 58 31 frequent (33%) Frequent (79-30%) HP:0010783
10 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
11 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
12 chronic fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012432
13 diabetes mellitus 58 31 frequent (33%) Frequent (79-30%) HP:0000819
14 hypercalcemia 58 31 frequent (33%) Frequent (79-30%) HP:0003072
15 muscle spasm 58 31 frequent (33%) Frequent (79-30%) HP:0003394
16 poor appetite 58 31 frequent (33%) Frequent (79-30%) HP:0004396
17 episodic abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002574
18 normochromic anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001895
19 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
20 intrahepatic cholestasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001406
21 extrahepatic cholestasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012334
22 intermittent jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0001046
23 abnormal gastrointestinal motility 58 31 occasional (7.5%) Occasional (29-5%) HP:0030895
24 respiratory insufficiency due to muscle weakness 58 31 very rare (1%) Very rare (<4-1%) HP:0002747
25 increased circulating gonadotropin level 58 31 very rare (1%) Very rare (<4-1%) HP:0000837
26 follicular thyroid carcinoma 58 31 very rare (1%) Very rare (<4-1%) HP:0006731
27 growth hormone excess 58 31 very rare (1%) Very rare (<4-1%) HP:0000845
28 neoplasm of the liver 58 31 very rare (1%) Very rare (<4-1%) HP:0002896
29 ganglioneuroma 58 31 very rare (1%) Very rare (<4-1%) HP:0003005
30 subcutaneous lipoma 58 31 very rare (1%) Very rare (<4-1%) HP:0001031
31 parathyroid adenoma 58 31 very rare (1%) Very rare (<4-1%) HP:0002897
32 adrenocortical adenoma 58 31 very rare (1%) Very rare (<4-1%) HP:0008256
33 pituitary adenoma 58 31 very rare (1%) Very rare (<4-1%) HP:0002893
34 primary hyperparathyroidism 58 31 very rare (1%) Very rare (<4-1%) HP:0008200
35 elevated calcitonin 58 31 very rare (1%) Very rare (<4-1%) HP:0003528
36 increased circulating prolactin concentration 58 31 very rare (1%) Very rare (<4-1%) HP:0000870
37 benign gastrointestinal tract tumors 58 31 very rare (1%) Very rare (<4-1%) HP:0006719
38 increased circulating cortisol level 31 very rare (1%) HP:0003118
39 hematochezia 58 Excluded (0%)
40 abnormality of the thyroid gland 58 Very rare (<4-1%)
41 hypercortisolism 58 Very rare (<4-1%)
42 abnormality of the abdomen 58 Occasional (29-5%)

UMLS symptoms related to Vipoma:


diarrhea

Drugs & Therapeutics for Vipoma

Drugs for Vipoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
3
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
4
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 6857599 5310940 9887054
6
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
9 Liver Extracts Phase 3
10 Cola Phase 3
11 Anesthetics Phase 3
12 Narcotics Phase 3
13 Analgesics Phase 3
14 Analgesics, Opioid Phase 3
15 Anesthetics, General Phase 3
16 Anesthetics, Intravenous Phase 3
17 Immunologic Factors Phase 2, Phase 3
18 Angiogenesis Inhibitors Phase 2, Phase 3
19 Immunosuppressive Agents Phase 2, Phase 3
20 Micronutrients Phase 2, Phase 3
21 Vitamins Phase 2, Phase 3
22 Antidotes Phase 2, Phase 3
23 Vitamin B Complex Phase 2, Phase 3
24 Folate Phase 2, Phase 3
25 Nutrients Phase 2, Phase 3
26 Trace Elements Phase 2, Phase 3
27 Vitamin B9 Phase 2, Phase 3
28 Protective Agents Phase 2, Phase 3
29 Antineoplastic Agents, Immunological Phase 2, Phase 3
30
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
31
Melphalan Approved Phase 2 148-82-3 460612 4053
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
34
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
37
Imetelstat Investigational Phase 2 868169-64-6
38 Anti-Bacterial Agents Phase 2
39 Anti-Infective Agents Phase 2
40 Epothilones Phase 2
41 Tubulin Modulators Phase 2
42 Epothilone B Phase 2
43 Antimitotic Agents Phase 2
44 topoisomerase I inhibitors Phase 2
45 Calcium, Dietary Phase 2
46 Retinol palmitate Phase 2
47 retinol Phase 2
48
Motesanib diphosphate Phase 2 850649-62-6 11450633
49 Immunoglobulins Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
4 EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
5 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
6 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
7 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
8 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
9 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
10 Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
11 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
12 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
13 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
14 A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00006368 Phase 1
15 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
16 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
17 Phase I Feasibility Trial To Study The Safety Of Sealing Resected Pancreatic Surfaces After Partial Distal Pancreatectomy Using Laser Tissue Welding Recruiting NCT03147768 Phase 1
18 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
19 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
20 Epidemiology of Chronic Diarrhea Among Children Admitted to Gastroenterology Unit at Assuit University Children Hospital Unknown status NCT03261297
21 Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients With G.I.-Related Neuroendocrine Tumours Unknown status NCT00454376
22 A Multi-center, Registration Study for Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893

Search NIH Clinical Center for Vipoma

Cochrane evidence based reviews: vipoma

Genetic Tests for Vipoma

Anatomical Context for Vipoma

MalaCards organs/tissues related to Vipoma:

40
Pancreas, Liver, Small Intestine, Testes, Thyroid, Endothelial, Pituitary

Publications for Vipoma

Articles related to Vipoma:

(show top 50) (show all 303)
# Title Authors PMID Year
1
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. 54 61
19184565 2009
2
VIPomas: an update in diagnosis and management in a series of 11 patients. 61 54
16001675 2005
3
Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas. 61 54
15816491 2005
4
[Jejunal vipoma]. 61 54
15646540 2004
5
Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. 54 61
12181718 2002
6
Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. 61 54
10638600 2000
7
Functional pancreatic islet cell tumors with liver metastasis: the role of cytoreductive surgery and transcatheter arterial chemoembolization: a report of five cases. 54 61
9884450 1998
8
Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. 54 61
9744346 1998
9
Expression of peptide receptors in human endocrine tumours of the pancreas. 61 54
9071943 1997
10
[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide]. 61 54
7588006 1995
11
Liver VIPoma: report of two cases and literature review. 54 61
7950821 1994
12
In vitro release of vasoactive intestinal polypeptide and pancreatic polypeptide from human VIPoma cells and its inhibition by somatostatin analogue (SMS 201-995). 54 61
8197564 1994
13
Tc-99m sestamibi imaging of a pancreatic VIPoma and parathyroid adenoma in a patient with multiple type I endocrine neoplasia. 61 54
7914844 1994
14
Stimulation of vasoactive intestinal peptide and neurotensin secretion by pentagastrin in a patient with VIPoma syndrome. 54 61
8128360 1994
15
Chromogranin A(210-301) is the major form of pancreastatin-like material in human gut extracts and endocrine tumors. 54 61
7984507 1994
16
Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma. 54 61
8266771 1993
17
Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome. 61 54
8383153 1993
18
[VIPoma: surgical treatment]. 61 54
1314346 1992
19
[Somatostatin in preoperative therapy and postoperative diagnosis of a patient with Verner Morrison syndrome]. 54 61
1282641 1992
20
[The somatostatin analog SMS 201-995 in long-term treatment of vipoma]. 61 54
2177234 1990
21
Future medical prospects for Sandostatin. 61 54
2205787 1990
22
Future medical prospects for Sandostatin. 54 61
1980778 1990
23
[Vipoma in an adolescent: treatment with a delayed-action somatostatin analog, octreotide or SMS 201-995, and surgical removal]. 54 61
2176428 1990
24
Incidental 68Ga-DOTATATE uptake in the pancreatic head: A case report and a unique opportunity to improve clinical care. 61
32481385 2020
25
Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide. 61
32168252 2020
26
A Rare Cause of Refractory Chronic Diarrhea and Cachexia: A Case Report. 61
32461947 2020
27
Neuroendocrine pancreatic tumor causing chronic diarrhea in young adult, a case report. 61
32420536 2020
28
[Use of a somatostatin analog to improve a patient's condition and the subsequent diagnosis of pancreatic VIPoma:a case report]. 61
31941861 2020
29
Successful Treatment of Hypokalemic Rhabdomyolysis Caused by a Pancreatic VIPoma: A Case Report. 61
31754090 2019
30
Life-threating diarrhea and acute renal failure secondary to pancreatic VIPoma treated by surgery. 61
31232078 2019
31
Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients. 61
31268974 2019
32
Pancreatic neuroendocrine microadenomatosis presenting as a functional VIPoma. 61
31275551 2019
33
Prevalence of Diagnostic Methods and Treatment Modalities in Vipoma Patients: A Rare Cause of Hormone-Mediated Diarrhea. 61
31641634 2019
34
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. 61
30566620 2019
35
Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. 61
31127985 2019
36
Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1. 61
30288555 2019
37
Perioperative Hypotensive Crisis in an Adolescent with a Pancreatic VIPoma and MEN1-Gene Variant. 61
30326482 2019
38
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma. 61
31123451 2019
39
Pancreatic VIPomas from China: Case reports and literature review. 61
30391116 2019
40
Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature. 61
30510956 2018
41
[Surgical strategies for small sporadic neuroendocrine pancreatic tumors]. 61
29637243 2018
42
Paediatric VIPoma: A Jamboree of Electrolytes. 61
29744252 2018
43
[VIPoma : a rare etiology of diarrhea with hypokalemia]. 61
29384277 2018
44
[A Surgical Resected Case of VIPoma with Para-Aortic Lymph Node Involvement]. 61
29394839 2017
45
Percutaneous Irreversible Electroporation for Pancreatic VIPoma: A Case Report. 61
27977628 2017
46
Verner-Morrison syndrome. Literature review. 61
28730220 2017
47
Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report. 61
27583474 2016
48
Ventricular fibrillation resulting from electrolyte imbalance reveals vipoma in MEN1 syndrome. 61
27071757 2016
49
Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization? 61
27583030 2016
50
Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution. 61
27170574 2016

Variations for Vipoma

Expression for Vipoma

Search GEO for disease gene expression data for Vipoma.

Pathways for Vipoma

GO Terms for Vipoma

Cellular components related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 SST SCT GHRH GH1 GAST CHGA
2 neuron projection GO:0043005 9.46 VIP SSTR3 GHRH CALCA
3 extracellular region GO:0005576 9.32 VIP SST SPINK5 SCT NTS GHRH

Biological processes related to Vipoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.76 SSTR3 SST SMAD4 MEN1
2 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.58 VIP GHRH CALCA
3 neuropeptide signaling pathway GO:0007218 9.5 SSTR3 NTS CALCA
4 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 9.49 SMAD4 MEN1
5 positive regulation of blood vessel diameter GO:0097755 9.48 VIP CALCA
6 cell-cell signaling GO:0007267 9.46 SSTR3 SST GHRH CALCA
7 response to food GO:0032094 9.43 GHRH GAST
8 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.37 GHRH GH1
9 response to transforming growth factor beta GO:0071559 9.26 SMAD4 MEN1
10 G protein-coupled receptor signaling pathway GO:0007186 9.23 VIP SSTR3 SST SCT NTS GHRH
11 hormone-mediated apoptotic signaling pathway GO:0008628 8.96 SSTR3 SST

Molecular functions related to Vipoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 R-SMAD binding GO:0070412 9.26 SMAD4 MEN1
2 hormone activity GO:0005179 9.17 VIP SST SCT GHRH GH1 GAST
3 peptide hormone receptor binding GO:0051428 9.16 VIP GHRH
4 neuropeptide hormone activity GO:0005184 9.13 VIP NTS GHRH

Sources for Vipoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....